The adjustment in price target by Chardan Capital reflects a positive outlook on SAB Biotherapeutics, especially after the reverse stock split. This action typically aims to increase the market price of a company's shares, making them more appealing to investors. The analyst's decision to maintain a Buy rating and significantly increase the price target suggests a strong belief in the company's future performance, potentially leading to increased investor interest and a positive short-term impact on the stock price.